Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
NV
NVOH
NV
Novo Nordisk A/S (B Shares) ADRhedged
NVOH
News
·
Is Viking Therapeutics a Buy Right Now?
Mkt Cap
N/A
Volume
518
Next Earnings
N/A
Chart
Earnings
News
About
Dividends
Insider
Filings
Is Viking Therapeutics a Buy Right Now?
Viking Therapeutics (VKTX) is a biotech company developing a weight loss drug candidate that has shown promising results in clinical trials. The company aims to launch a phase 3 trial for the injectable version of VK2735 in the second quarter. Despite recent stock declines, the article suggests that Viking could be a good buy considering the high-growth weight loss drug market opportunity and the company's progress.
The Motley Fool · Feb 26, 2025
Why Eli Lilly Stock Popped Today
Eli Lilly announced plans to acquire Organovo's FXR program and launched larger-dose vials of its weight loss drug Zepbound at lower prices, causing its stock to rise 2.6% despite a market downturn.
The Motley Fool · Feb 25, 2025
Disney Earnings: Is It Time to Buy the Magic Kingdom?
The article discusses Disney's (DIS) first-quarter earnings report, providing an overview of the company's performance and financial results.
The Motley Fool · Feb 6, 2025
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
NV
NVOH
Novo Nordisk A/S (B Shares) ADRhedged
Buy
Sell
Market
Limit
Soon
NVOH
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any NVOH yet.
Related Tickers
Earnings
Dividends
Last · Sep 16
Quarterly
Amount
$0.0300
Yield
7.16%
Annual
$1.56